RT Journal Article
T1 Time is lung: higher preservation of lung function in severe asthma patients after earlier mepolizumab treatment
A1 González Barcala, Francisco Javier
A1 Bobolea, Irina
A1 Domínguez-Ortega, Javier
A1 Bañas-Conejero, David
A1 Antelo-Cea, Esteban
A1 Martínez-Moragón, Eva
A1 Carrillo-Díaz, Teresa
A1 Blanco-Aparicio, Marina
A1 Domingo, Christian
AB Introduction Severe asthma involves a persistent inflammation of the airways that is associated with a greater risk of exacerbations. Exacerbations are associated with a higher lung function decline over time. The prevention of lung function decline could become a strategy for disease modification, and this could be more likely to happen in patients with an earlier therapeutic approach. Thus, this study means to analyse the effect of asthma duration in clinical outcomes such as lung function in patients from the REDES study. REDES was an observational real-world study that assessed the effectiveness and safety of mepolizumab 100 mg s.c. every 4 weeks for 12 months in 318 patients with severe asthma in Spain. Methods This post hoc analysis evaluated how disease duration affected the study results through a stratification according to quartiles on their disease progression. Continuous analyses were also performed to assess the impact of confounder variables on forced expiratory volume in 1 s (FEV1) (%). Results At baseline, patients with shorter time of disease had a significantly higher lung function than patients with longer asthma duration. At 12 months, pre-bronchodilator (BD) FEV1 values and the proportion of patients with (Formula Presented)80% pre-BD FEV1 were higher according to a shorter disease persistence (Q1>Q2>Q3>Q4). Conclusion These results support that time of disease persistence contributes to the lung function decline of patients with severe asthma, uncontrolled while on previous treatment, and that an earlier approach with mepolizumab may imply a higher preservation of their lung function.
PB European Respiratory Society
SN 2312-0541
YR 2025
FD 2025
LK https://hdl.handle.net/10347/45710
UL https://hdl.handle.net/10347/45710
LA eng
NO González-Barcala, F.-J., Bobolea, I., Domínguez-Ortega, J., Bañas-Conejero, D., Antelo-Cea, E., Martínez-Moragón, E., Carrillo-Díaz, T., Blanco-Aparicio, M., & Domingo, C. (2025). Time is lung: higher preservation of lung function in severe asthma patients after earlier mepolizumab treatment. ERJ Open Research, 11(1). https://doi.org/10.1183/23120541.00211-2024
NO This study was funded by GlaxoSmithKline (study number 213172).
DS Minerva
RD 27 abr 2026